Ch'ng Yung Sing, Loh Yean Chun, Tan Chu Shan, Ahmad Mariam, Asmawi Mohd Zaini, Wan Omar Wan Maznah, Yam Mun Fei
1 Department of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia , Minden, Pulau Pinang, Malaysia .
2 School of Biological Sciences, Universiti Sains Malaysia , Minden, Pulau Pinang, Malaysia .
J Med Food. 2018 Mar;21(3):289-301. doi: 10.1089/jmf.2017.4008. Epub 2018 Feb 8.
The seeds of Swietenia macrophylla King (SM) (Meliaceae) are used as a folk medicine for the treatment of hypertension in Malaysia. However, the antihypertensive and vasorelaxant effects of SM seeds are still not widely studied. Thus, this study was designed to investigate the in vivo antihypertensive effects and in vitro mechanism of vasorelaxation of a 50% ethanolic SM seed extract (SM50) and the fingerprint of SM50 was developed through tri-step Fourier transform infrared (FTIR) spectroscopy. The vasorelaxant activity and the underlying mechanisms of SM50 were evaluated on thoracic aortic rings isolated from Sprague-Dawley rats in the presence of antagonists. The pharmacological effect of SM50 was investigated by oral administration of spontaneously hypertensive rats (SHRs) with three different doses of SM50 (1000, 500, and 250 mg/kg/day) for 4 weeks and their systolic blood pressure (SBP) and diastolic blood pressure (DBP) values were measured weekly using tail-cuff method. The tri-step FTIR macro-fingerprint of SM50 showed that SM50 contains stachyose, flavonoids, limonoids, and ester, which may contribute to its vasorelaxant effect. The results showed that the vasorelaxant activity of SM50 was mostly attributed to channel-linked receptors pathways through the blockage of voltage-operated calcium channels (VOCC). SM50 also acts as both potassium channels opener and inositol triphosphate receptor (IPR) inhibitor, followed by β-adrenergic pathway, and ultimately mediated through the nitric oxide/soluble guanylyl cyclase/cyclic 3',5'-guanosine monophosphate (NO/sGC/cGMP) signaling pathways. The treatment of SM50 also significantly decreased the SBP and DBP in SHRs. In conclusion, the antihypertensive mechanism of SM50 was mediated by VOCC, K channels, IPR, G-protein-coupled β-adrenergic receptor, and followed by NO/sGC/cGMP signaling mechanism pathways in descending order. The data suggested that SM50 has the potential to be used as a herbal medicament to treat hypertension.
大叶桃花心木(Swietenia macrophylla King,SM)(楝科)种子在马来西亚被用作治疗高血压的民间药物。然而,SM种子的降压和血管舒张作用尚未得到广泛研究。因此,本研究旨在探讨50%乙醇SM种子提取物(SM50)的体内降压作用和体外血管舒张机制,并通过三步傅里叶变换红外(FTIR)光谱法建立SM50的指纹图谱。在存在拮抗剂的情况下,对从Sprague-Dawley大鼠分离的胸主动脉环评估SM50的血管舒张活性及其潜在机制。通过对自发性高血压大鼠(SHR)口服三种不同剂量的SM50(1000、500和250 mg/kg/天)持续4周来研究SM50的药理作用,并每周使用尾套法测量其收缩压(SBP)和舒张压(DBP)值。SM50的三步FTIR宏观指纹图谱表明,SM50含有水苏糖、黄酮类化合物、柠檬苦素和酯类,这可能有助于其血管舒张作用。结果表明,SM50的血管舒张活性主要归因于通过阻断电压门控钙通道(VOCC)的通道连接受体途径。SM50还可作为钾通道开放剂和肌醇三磷酸受体(IPR)抑制剂,其次是β-肾上腺素能途径,并最终通过一氧化氮/可溶性鸟苷酸环化酶/环3',5'-鸟苷单磷酸(NO/sGC/cGMP)信号通路介导。SM50治疗也显著降低了SHR的SBP和DBP。总之,SM50的降压机制由VOCC、钾通道、IPR、G蛋白偶联β-肾上腺素能受体介导,随后依次为NO/sGC/cGMP信号机制途径。数据表明,SM50有潜力用作治疗高血压的草药药物。